Why the study?
Does intravenous enoxaparin differ from standard heparin in pharmacokinetics and biodistribution in normal volunteers?
Population
4 normal volunteers
Comparison
99m technetium labelled enoxaparin administered… vs 99m technetium labelled standard heparin…
Design
Other
Authors
Loading...
Enoxaparin's longer anti-Xa half-life may inform dosing intervals in volunteers; leaves open mechanisms and clinical relevance in patients.
Does intravenous enoxaparin differ from standard heparin in pharmacokinetics and biodistribution in normal volunteers?
The longer anti-Xa half-life of enoxaparin compared to standard heparin is likely due to differences in metabolism or endogenous factor release rather than biodistribution.
Laforest et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: